Skip to main content

Table 1 mAb-Based Therapies Targeting Non-Immune Cells for PDAC

From: Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma

mAb Condition Target Cells Mechanism Status Reference
SS1(dsFv)-PE38 (SS1P) An anti-mesothelin Fv genetically fused with a truncated pseudomonas exotoxin, PE38 Mesothelin Cancer cells PE38 is internalized into and kills cancer cells through inhibition of protein synthesis by ADP ribosylation and inactivation of elongation factor 2 Clinical trials NCT01362790; NCT00006981
MORAb-009 Heavy and light chain variable regions of a mouse anti-mesothelin single chain Fv grafted to human IgG1 and κ constant regions Mesothelin Cancer cells Inhibits the adhesion between cells expressing mesothelin and MUC16 as well as mediates ADCC Clinical trials NCT00570713; NCT00325494; NCT01521325; NCT01413451
BAY94–9343 An ADC consisting of a human anti-mesothelin antibody conjugated to a tubulin inhibitor, DM4 Mesothelin Cancer cells Binds to human mesothelin and induces antigen internalization Clinical trials NCT03023722; NCT03816358; NCT03102320
GP1.4 Monoclonal antibody MUC1 Cancer cells Induces MUC1 internalization and inhibits ERK signalling, resulting in the suppression of PDAC cell proliferation and migration Preclinical study [78]
A novel produced monoclonal antibody Monoclonal antibody MUC1-C Cancer cells Induces MUC1 internalization and inhibits ERK signalling, resulting in the suppression of PDAC cell proliferation and migration Preclinical study [79]
A.4.6.1 Murine-derived monoclonal antibody VEGF Cancer cells Inhibits the angiogenesis of tumours Preclinical study [80]
Erlotinib Monoclonal antibody EGFR Cancer cells Inhibits the angiogenesis of tumours Clinical trials NCT00810719; NCT02154737; NCT02694536; NCT01782690; NCT00614653; NCT00640978; NCT00565487; NCT00313560; NCT01608841; NCT01303029
Bevacizumab Monoclonal antibody VEGF Cancer cells Inhibits the angiogenesis of tumours Clinical trials NCT00614653; NCT00047710; NCT00460174; NCT00365144; NCT00410774; NCT00417976; NCT00112528; NCT00602602; NCT00126633; NCT00366457
9E1 Monoclonal antibody AnxA6 Cancer cells, potential stromal cells Reduces the expression of MMP-9 and/or interferes with ERK and MEK signalling Preclinical study [81]
Demcizumab Monoclonal antibody DLL4 CSCs Decreases CSC frequency and interferes with angiogenesis Clinical trials [82]; NCT01189929; NCT02289898
Clivatuzumab (PAM4) 131I-labelled,90Y-labelled MUC1 Cancer cells Radioimmunotherapy Clinical trials [83]
TF10 (A humanized recombinant structure) 90Y-labelled MUC1 Cancer cells Radioimmunotherapy Preclinical study [83]
C595 213Bi-labelled MUC1 Cancer cells Radioimmunotherapy Preclinical study [83]
CC49 131I-labelled TAG-72 Cancer cells Radioimmunotherapy Preclinical study [83]
EGFR antibody 177Lu-labelled EGFR Cancer cells Radioimmunotherapy Preclinical study [83]
Trastuzumab 213Bi-labelled HER2 Cancer cells Radioimmunotherapy Preclinical study [83]
TNT3 antibodies 213Bi-labelled Single-strand DNA and RNA Released from necrotic cells Radioimmunotherapy Preclinical study [83]
KAb201 131I-labelled CEA Cancer cells Radioimmunotherapy Clinical trial [83]
MN-14 131I-labelled CEA Cancer cells Radioimmunotherapy Clinical trial [83]
TCMC-Trastuzumab 212Pb-labelled HER2 Cancer cells Radioimmunotherapy Clinical trial [83]
059–053 90Y-labelled CD147 Cancer cells Radioimmunotherapy Preclinical trial [84]
376.96 212Pb-labelled B7-H3 Cancer cells Radioimmunotherapy Preclinical trial [85]
TIBs derived IgG Unidentified multiclonal antibody G12 mutation-derived epitopes Cancer cells Targets mutation-derived and personalized antigens Preclinical study [86]